Form 4: Cellectar Biosciences Executive Andrei Shustov Granted Stock Options Following Shareholder Approval
SEC Form 4
Andrei Shustov, Senior Vice President, Medical at Cellectar Biosciences, received stock options for 260,000 shares after shareholder approval of the amended 2021 Stock Incentive Plan.
Summary
- Andrei Shustov, Senior Vice President, Medical at Cellectar Biosciences, was granted stock options to purchase 260,000 shares of common stock.
- The grant occurred on June 14, 2024, following shareholder approval of Cellectar's amended 2021 Stock Incentive Plan.
- The options have an exercise price of $2.65 per share and expire on December 15, 2033.
- The options vest over three years from December 15, 2023, with one-third vesting on the first anniversary and the remainder in 24 equal monthly installments.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a routine corporate action that aligns executive interests with shareholder value. There are no red flags or negative implications apparent in the filing.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the executive.
Future Outlook
This filing does not contain forward-looking statements about the company's future performance, but the granting of stock options suggests an expectation of future value creation.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. This grant is part of Cellectar's overall compensation strategy.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their executives.
- The vesting schedule and exercise price are typical for similar grants in comparable companies.
Stakeholder Impact
- Shareholders may view this as a positive sign, aligning management's interests with the company's success.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| December 15, 2023 | Date the option was contingently granted and vesting begins. |
| June 14, 2024 | Date of shareholder approval and official grant date. |
| December 15, 2033 | Expiration date of the stock options. |
Keywords
stock options, Cellectar Biosciences, executive compensation, shareholder approval, insider trading, CLRB, Andrei Shustov
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.